Empagliflozin effects in patients with myocardial infarctio
Phase 3
Completed
- Conditions
- Myocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20111206008307N42
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients with STEMI undergoing primary PCI
Patients aged between 18 to 80 years
Consented patients
Exclusion Criteria
Pregnancy
Lactation
Renal failure (eGFR < 30)
Hepatic failure
Systolic blood pressure less than 100 mmHg
Inflammatory and autoimmune diseases
Diabetes mellitus
Chronic heart failure
Cancer
Psychiatric disorders
Empagliflozin contraindications
History of receiving empagliflozin
History of myocardial infarction
Arrival more than 6 hours from symptoms onset
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method